AZN - Astrazeneca

-

$undefined

N/A

(N/A)

Astrazeneca NASDAQ:AZN AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England.

Location: 1 Francis Crick Avenue, Cambridgeshire, CB2 0AA, United Kingdom | Website: https://www.astrazeneca.com/home | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

145.8B

Cash

7.076B

Avg Qtr Burn

N/A

Short % of Float

0.35%

Insider Ownership

0.01%

Institutional Own.

17.03%

Qtr Updated

06/30/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Andexxa (andexanet alfa) Details
Intracranial haemorrhage

Phase 4

Update

Approved

Update

Approved

Update

Calquence (acalabrutinib) Details
Cancer, Blood cancer, Chronic lymphocytic leukemia, Small lymphocytic lymphoma

Approved

Update

Approved

Quarterly sales

Voydeya (Danicopan) Details
Paroxysmal nocturnal hemoglobinuria

Approved

Quarterly sales

Approved

Quarterly sales

Soliris (eculizumab) Details
Myasthenia gravis, Paroxysmal nocturnal hemoglobinuria , Atypical haemolytic uraemic syndrome

Approved

Quarterly sales

Imfinzi + Lynparza Details
Cancer, Solid tumor/s, Endometrial cancer

Approved

Quarterly sales

Approved

Quarterly sales

Imfinzi + chemotherapy (as neoadjuvant treatment) Details
Cancer, Non-small cell lung carcinoma, Lung cancer

Approved

Quarterly sales

Ultomiris Details
Rare diseases, Myasthenia gravis, Paroxysmal nocturnal hemoglobinuria , Atypical haemolytic uraemic syndrome, Neuromyelitis optica spectrum disorder (NMOSD)

Approved

Quarterly sales

Tagrisso Details
Lung cancer, Cancer, Non-small cell lung carcinoma

Approved

Quarterly sales

Fasenra Details
Coronary Microvascular Dysfunction, Eosinophilic granulomatosis with polyangiitis

Approved

Quarterly sales

Lynparza w/ abiraterone and prednisone or prednisolone Details
Solid tumor/s, Cancer, Castration-resistant prostate cancer

Approved

Quarterly sales

Approved

Quarterly sales

Tagrisso + chemotherapy Details
Lung cancer, Cancer, EGFR-mutated advanced lung cancer

Approved

Quarterly sales

Enhertu Details
Cancer, Solid tumor/s

Approved

Quarterly sales

Beyfortus (Nirsevimab) Details
Respiratory syncytial virus, Respiratory virus, Viral infection

Approved

Quarterly sales

Farxiga Details
Type 2 diabetes

Approved

Quarterly sales

PDUFA

Approval decision

Enhertu Details
Cancer, Breast cancer

PDUFA

Approval decision

Dato-DXd (Datopotamab deruxtecan) Details
Cancer, Non-small cell lung carcinoma, Lung cancer

PDUFA

Approval decision

Imfinzi (durvalumab) Details
Lung cancer, Cancer, Small cell lung cancer

PDUFA

Approval decision

NDA

Submission

Saphnelo Details
Idiopathic pulmonary fibrosis

Phase 3

Data readout

Orpathys + Tagrisso Details
Cancer, Solid tumor/s

Phase 3

Data readout

LYNPARZA Details
Cancer, Solid tumor/s, Ovarian cancer

Phase 3

Data readout

Calquence (acalabrutinib) + venetoclax +/- obinutuzumab Details
Cancer, Blood cancer, Chronic lymphocytic leukemia

Phase 3

Data readout

Tozorakimab Details
Respiratory conditions, Acute respiratory distress syndrome, Lung disease

Phase 3

Data readout

Imfinzi (durvalumab) Details
Cancer, Non-small cell lung carcinoma, Lung cancer

Phase 3

Data readout

LYNPARZA Details
Cancer, Solid tumor/s, Ovarian cancer

Phase 3

Data readout

Fasenra Details
Chronic rhinosinusitis with nasal polyps

Phase 3

Data readout

Phase 3

Data readout

Koselugo (selumetinib, MEK inhibitor) Details
Cancer, Solid tumor/s, Neurofibromatosis type 1

Phase 3

Data readout

Anselamimab (CAEL-101) Details
Amyloid light chain amyloidosis

Phase 3

Data readout

Tagrisso Details
Cancer, Lung cancer, Non-small cell lung carcinoma

Phase 3

Data readout

Dato-DXd Details
Cancer, Breast cancer

Phase 3

Data readout

Tezspire (tezepelumab) Details
Chronic rhinosinusitis with nasal polyps

Phase 3

Data readout

Imfinzi (mono/combo) Details
Cancer, Liver cancer

Phase 3

Data readout

Imfinzi comb w/ chemotherapy Details
Cancer, Gastroesophageal junction tumors, Gastric cancer

Phase 3

Update

roxadustat Details
Myelodysplastic syndrome, Anemia

Phase 3

Update

Phase 3

Update

Phase 3

Update

Imfinzi comb w/ chemotherapy Details
Cancer, Biliary Tract Cancer

Phase 3

Update

Imfinzi Details
Cancer, Bladder cancer

Phase 3

Update

Farxiga Details
Acute myocardial infarction

Phase 3

Update

Fasenra Details
Coronary Microvascular Dysfunction

Phase 3

Update

Capivasertib Details
Breast cancer, Cancer, Triple-negative breast cancer

Phase 3

Update

FPI-2265 Details
Prostate cancer, Cancer

Phase 2/3

Update

Phase 2b

Data readout

Baxdrostat Details
Primary aldosteronism

Phase 2

Data readout

Baxdrostat Details
Pulmonary hypertension

Phase 2

Data readout

Baxdrostat Details
Chronic kidney disease

Phase 2

Data readout

Phase 2

Data readout

Dato-DXd (Datopotamab deruxtecan) Details
Non-small cell lung carcinoma, Cancer, Lung cancer

Phase 2

Data readout

Anselamimab (CAEL-101) Details
Amyloid light chain amyloidosis

Phase 2

Data readout

Enhertu Details
Cancer, Non-small cell lung carcinoma

Phase 2

Update

Dato-DXd (Datopotamab deruxtecan) Details
Non-small cell lung carcinoma, Cancer, Lung cancer, Solid tumor/s, Triple-negative breast cancer

Phase 1/2

Data readout

LB-001 Details
Methylmalonic acidemia, Genetic disorder, Rare genetic disease

Phase 1/2

Interim update

ECC5004 Details
Obesity, Type 2 diabetes

Phase 1

Data readout

Phase 1

Data readout

FPI-2068 Details
Solid tumor/s, Cancer

Phase 1

Update

FPI-2059 Details
Solid tumor/s, Cancer

Phase 1

Update

Dato-DXd (Datopotamab deruxtecan) Details
Non-small cell lung carcinoma, Lung cancer, Cancer

Phase 1

Update

Phase 1

Update